CoChat
Sign Up
Cited by 2

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Cardiovascular Health and Outcomes in Carriers With Genetic Variants of Hypertrophic Cardiomyopathy

Patel, Nirav, Gaonkar, Mokshad, Pampana, Akhil, Dhaliwal, Jasninder S., Vekariya, Nehal, Shetty, Naman S., Li, Peng, Kalra, Rajat, Arora, Garima, Arora, Pankaj·2026·Mayo Clinic Proceedings
DOI 10.1016/j.mayocp.2024.12.018PMC PMC13229500
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mayocp.2024.12.018

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 1 references

Research works printed but not linked: 65

  1. Alfares, 2015, Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity, Genet Med, 17, 880, 10.1038/gim.2014.205 · DOI · Paper page
  2. Ho, 2018, Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe), Circulation, 138, 1387, 10.1161/CIRCULATIONAHA.117.033200 · DOI · Paper page
  3. Kelly, 2018, Adaptation and validation of the ACMG/AMP variant classification framework for associated inherited cardiomyopathies: recommendations by ClinGen's Inherited Cardiomyopathy Expert Panel, Genet Med, 20, 351, 10.1038/gim.2017.218 · DOI
  4. Ho, 2019, Response by Ho et al to letter regarding article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe).", Circulation, 139, 1559, 10.1161/CIRCULATIONAHA.118.039069 · DOI
  5. Writing Committee Members, 2024, 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines, J Am Coll Cardiol, 83, 2324, 10.1016/j.jacc.2024.02.014 · DOI
  6. de Marvao, 2021, Phenotypic expression and outcomes in individuals with rare genetic variants of hypertrophic cardiomyopathy, J Am Coll Cardiol, 78, 1097, 10.1016/j.jacc.2021.07.017 · DOI
  7. Lau, 2017, Modifiable risk factors and atrial fibrillation, Circulation, 136, 583, 10.1161/CIRCULATIONAHA.116.023163 · DOI
  8. Yusuf, 2020, Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study, Lancet, 395, 795, 10.1016/S0140-6736(19)32008-2 · DOI · Paper page
  9. Ahmad, 2016, Hypertension, obesity, diabetes, and heart failure–free survival, JACC Heart Fail, 4, 911, 10.1016/j.jchf.2016.08.001 · DOI
  10. Hasbani, 2022, American Heart Association's Life's Simple 7: lifestyle recommendations, polygenic risk, and lifetime risk of coronary heart disease, Circulation, 145, 808, 10.1161/CIRCULATIONAHA.121.053730 · DOI
  11. Zhu, 2022, Association of lifestyle with incidence of heart failure according to metabolic and genetic risk status: a population-based prospective study, Circ Heart Fail, 15, 10.1161/CIRCHEARTFAILURE.122.009592 · DOI
  12. Parcha, 2022, Association of a multiancestry genome-wide blood pressure polygenic risk score with adverse cardiovascular events, Circ Genom Precis Med, 15, 10.1161/CIRCGEN.122.003946 · DOI
  13. Shetty, 2024, Titin truncating variants, cardiovascular risk factors and the risk of atrial fibrillation and heart failure, Nat Cardiovasc Res, 3, 899, 10.1038/s44161-024-00511-2 · DOI
  14. Shetty, 2025, Cardiovascular risk factors and genetic risk in transthyretin V142I carriers, JACC Heart Fail, 13, 91, 10.1016/j.jchf.2024.08.019 · DOI
  15. Akinrinade, 2016, Relevance of truncating titin mutations in dilated cardiomyopathy, Clin Genet, 90, 49, 10.1111/cge.12741 · DOI
  16. Sudlow, 2015, UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age, PLoS Med, 12, 10.1371/journal.pmed.1001779 · DOI · Paper page
  17. Backman, 2021, Exome sequencing and analysis of 454,787 UK Biobank participants, Nature, 599, 628, 10.1038/s41586-021-04103-z · DOI
  18. Van Hout, 2020, Exome sequencing and characterization of 49,960 individuals in the UK Biobank, Nature, 586, 749, 10.1038/s41586-020-2853-0 · DOI · Paper page
  19. Ingles, 2019, Evaluating the clinical validity of hypertrophic cardiomyopathy genes, Circ Genom Precis Med, 12, 10.1161/CIRCGEN.119.002460 · DOI
  20. Bourfiss, 2022, Prevalence and disease expression of pathogenic and likely pathogenic variants associated with inherited cardiomyopathies in the general population, Circ Genom Precis Med, 15, 10.1161/CIRCGEN.122.003704 · DOI
  21. Bycroft, 2018, The UK Biobank resource with deep phenotyping and genomic data, Nature, 562, 203, 10.1038/s41586-018-0579-z · DOI · Paper page
  22. Drozd, 2021, Causes of death in people with cardiovascular disease: a UK Biobank cohort study, J Am Heart Assoc, 10, 10.1161/JAHA.121.023188 · DOI
  23. Lloyd-Jones, 2022, Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a Presidential Advisory From the American Heart Association, Circulation, 146, e18, 10.1161/CIR.0000000000001078 · DOI · Paper page
  24. Shetty, 2023, Trends of cardiovascular health in Asian American individuals: a national health and nutrition examination survey study, Am J Prev Cardiol, 14, 10.1016/j.ajpc.2023.100509 · DOI
  25. Shetty, 2024, Association of Life's Essential 8 and Simple 7 scores with mortality: comparison with pooled cohort equation, JACC Adv, 3, 10.1016/j.jacadv.2024.100945 · DOI
  26. Shetty, 2023, AHA Life's Essential 8 and ideal cardiovascular health among young adults, Am J Prev Cardiol, 13, 10.1016/j.ajpc.2022.100452 · DOI
  27. Woodward, 2021, Social deprivation as a risk factor for COVID-19 mortality among women and men in the UK Biobank: nature of risk and context suggests that social interventions are essential to mitigate the effects of future pandemics, J Epidemiol Community Health, 75, 1050, 10.1136/jech-2020-215810 · DOI
  28. Kuitunen, 2021, Testing the proportional hazards assumption in Cox regression and dealing with possible non-proportionality in total joint arthroplasty research: methodological perspectives and review, BMC Musculoskelet Disord, 22, 489, 10.1186/s12891-021-04379-2 · DOI
  29. Walker, 2018, Prevalence and predictors of sepsis death in patients with chronic heart failure and reduced left ventricular ejection fraction, J Am Heart Assoc, 7, 10.1161/JAHA.118.009684 · DOI
  30. Shah, 2014, Comparison of random forest and parametric imputation models for imputing missing data using MICE: a CALIBER study, Am J Epidemiol, 179, 764, 10.1093/aje/kwt312 · DOI
  31. Burke, 2016, Clinical and mechanistic insights into the genetics of cardiomyopathy, J Am Coll Cardiol, 68, 2871, 10.1016/j.jacc.2016.08.079 · DOI
  32. Kaski, 2009, Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy, Circ Cardiovasc Genet, 2, 436, 10.1161/CIRCGENETICS.108.821314 · DOI
  33. Maron, 2022, Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC State-of-the-Art Review, J Am Coll Cardiol, 79, 372, 10.1016/j.jacc.2021.12.002 · DOI · Paper page
  34. Kirschner, 2005, Hypertrophic cardiomyopathy–related beta-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells, Am J Physiol Heart Circ Physiol, 288, H1242, 10.1152/ajpheart.00686.2004 · DOI
  35. Lim, 2001, Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes, J Am Coll Cardiol, 38, 1175, 10.1016/S0735-1097(01)01509-1 · DOI
  36. Ho, 2010, Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy, N Engl J Med, 363, 552, 10.1056/NEJMoa1002659 · DOI
  37. Maron, 2013, Hypertrophic cardiomyopathy, Lancet, 381, 242, 10.1016/S0140-6736(12)60397-3 · DOI · Paper page
  38. Maron, 2018, Clinical course and management of hypertrophic cardiomyopathy, N Engl J Med, 379, 655, 10.1056/NEJMra1710575 · DOI · Paper page
  39. Sivalokanathan, 2019, Hypertrophic cardiomyopathy patients with paroxysmal atrial fibrillation have a high burden of left atrial fibrosis by cardiac magnetic resonance imaging, JACC Clin Electrophysiol, 5, 364, 10.1016/j.jacep.2018.10.016 · DOI
  40. Ommen, 2020, 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, J Am Coll Cardiol, 76, e159, 10.1016/j.jacc.2020.08.045 · DOI · Paper page
  41. Coppini, 2014, Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations, J Am Coll Cardiol, 64, 2589, 10.1016/j.jacc.2014.09.059 · DOI
  42. Saul, 2024, Natural history and clinical outcomes of patients with hypertrophic cardiomyopathy from thin filament mutations, ESC Heart Fail, 11, 3501, 10.1002/ehf2.14848 · DOI
  43. Rowin, 2017, Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy, Circulation, 136, 2420, 10.1161/CIRCULATIONAHA.117.029267 · DOI · Paper page
  44. Tripathi, 2019, Burden and trends of arrhythmias in hypertrophic cardiomyopathy and its impact of mortality and resource utilization, J Arrhythm, 35, 612, 10.1002/joa3.12215 · DOI
  45. Marian, 2021, Molecular genetic basis of hypertrophic cardiomyopathy, Circ Res, 128, 1533, 10.1161/CIRCRESAHA.121.318346 · DOI · Paper page
  46. Lopes, 2024, Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice, Eur Heart J, 45, 2727, 10.1093/eurheartj/ehae421 · DOI
  47. Harper, 2021, Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity, Nat Genet, 53, 135, 10.1038/s41588-020-00764-0 · DOI · Paper page
  48. Tadros, 2021, Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect, Nat Genet, 53, 128, 10.1038/s41588-020-00762-2 · DOI
  49. Lopes, 2022, Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry, Eur Heart J Qual Care Clin Outcomes, 9, 42, 10.1093/ehjqcco/qcac006 · DOI · Paper page
  50. Hajouli, 2024, Is type 2 diabetes mellitus an independent risk factor for mortality in hypertrophic cardiomyopathy?, Cardiol Res, 15, 198, 10.14740/cr1659 · DOI
  51. Lee, 2022, Impact of diabetes mellitus on the outcomes of subjects with hypertrophic cardiomyopathy: a nationwide cohort study, Diabetes Res Clin Pract, 186, 10.1016/j.diabres.2022.109838 · DOI
  52. Jex, 2022, Coexistent diabetes is associated with the presence of adverse phenotypic features in patients with hypertrophic cardiomyopathy, Diabetes Care, 45, 1852, 10.2337/dc22-0083 · DOI
  53. Fumagalli, 2020, Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy, JAMA Cardiol, 5, 65, 10.1001/jamacardio.2019.4268 · DOI
  54. Wasserstrum, 2019, The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy, Eur Heart J, 40, 1671, 10.1093/eurheartj/ehy625 · DOI · Paper page
  55. Maron, 2013, Risk stratification and outcome of patients with hypertrophic cardiomyopathy ≥60 years of age, Circulation, 127, 585, 10.1161/CIRCULATIONAHA.112.136085 · DOI · Paper page
  56. Maron, 2021, Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: twenty years with the implantable cardioverter-defibrillator, Heart Rhythm, 18, 1012, 10.1016/j.hrthm.2021.01.019 · DOI
  57. Carrick, 2021, Development and validation of a clinical predictive model for identifying hypertrophic cardiomyopathy patients at risk for atrial fibrillation: the HCM-AF score, Circ Arrhythm Electrophysiol, 14, 10.1161/CIRCEP.120.009796 · DOI
  58. Guttmann, 2014, Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review, Heart, 100, 465, 10.1136/heartjnl-2013-304276 · DOI
  59. Wilke, 2016, High incidence of de novo and subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management device, J Cardiovasc Electrophysiol, 27, 779, 10.1111/jce.12982 · DOI
  60. Rowin, 2014, Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant, Circ Heart Fail, 7, 967, 10.1161/CIRCHEARTFAILURE.114.001435 · DOI
  61. Lu, 2022, Risk factors, clinical features, and outcomes of patients with hypertrophic cardiomyopathy complicated by ischemic stroke: a single-center retrospective study, Front Cardiovasc Med, 9, 10.3389/fcvm.2022.1054199 · DOI
  62. Sweeting, 2016, Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers, Open Heart, 3, 10.1136/openhrt-2016-000484 · DOI
  63. Saberi, 2017, Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: a randomized clinical trial, JAMA, 317, 1349, 10.1001/jama.2017.2503 · DOI · Paper page
  64. Klempfner, 2015, Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: results of a structured exercise training program in a cardiac rehabilitation center, Eur J Prev Cardiol, 22, 13, 10.1177/2047487313501277 · DOI
  65. Lampert, 2023, Vigorous exercise in patients with hypertrophic cardiomyopathy, JAMA Cardiol, 8, 595, 10.1001/jamacardio.2023.1042 · DOI · Paper page

Cited by

Sorted by citations

See all 2

Metadata

Authors
Patel, N., Gaonkar, M., Pampana, A., Dhaliwal, J. S., Vekariya, N., Shetty, N. S., Li, P., Kalra, R., Arora, G., & Arora, P.
ORCID
Arora, Pankaj
Venue
Mayo Clinic Proceedings
Publisher
Elsevier BV
Published
2026-01
Volume
101
Issue
1
Pages
73-84
ISSN
0025-6196
DOI
10.1016/j.mayocp.2024.12.018
PMC
PMC13229500
Cited by
2
References
1
Language
en
Licence
Funders
  • National Heart Lung and Blood Institute Division of Intramural Research (R01HL163081, R01HL163852, R01HL160982)
  • National Heart, Lung, and Blood Institute
  • National Institutes of Health (16/NW/0274, 58838)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review